Sellas presents preclinical data on SLS009 CDK9 inhibitor in pancreatic cancer organoid models at AACR conference

Sellas Life Sciences disclosed preclinical pancreatic cancer data for SLS009, a CDK9 inhibitor, from patient-derived organoid studies. Results are being presented at the AACR Conference on Pancreatic Cancer, running Sept. 25-28, 2026, in San Diego. SLS009 showed stronger single-agent anti-tumor activity than a RAS inhibitor in a resistant, MYC-amplified pancreatic cancer model. Combining SLS009 with the RAS inhibitor increased cancer cell death, supporting a potential strategy to address resistance to RAS-directed therapy. A separate study pairing SLS009 with BET inhibition produced synergistic activity, consistent with suppressing MYC-driven survival programs. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sellas Life Sciences Group Inc. published the original content used to generate this news brief via (Ref. ID: 202609251300PRIMZONEFULLFEED9834139) on September 25, 2026, and is solely responsible for the information conta